While developing apolipoprotein-mimetic peptides, a team at Scripps Research made an interesting discovery.
Several short, unrelated sequences, included only as negative controls, all lowered plasma cholesterol in mice.
They weren't supposed to do anything.
The explanation, set out in a 2025 preprint, had nothing to do with the sequences. It was trifluoroacetate (TFA), the counterion that standard HPLC purification leaves behind, which was found to be biologically active in its own right.1
This story captures something that peptide developers often learn the expensive way: a molecule can be exactly what its certificate says and still be wrong for the next job.
Quality requirements rise in fairly predictable steps as a programme moves from the bench towards patients … and teams that plan for each step tend to redo less work later.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.
